Lido Advisors LLC trimmed its position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 58.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,490 shares of the biopharmaceutical company’s stock after selling 14,668 shares during the period. Lido Advisors LLC’s holdings in Royalty Pharma were worth $612,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of RPRX. Provenance Wealth Advisors LLC acquired a new stake in Royalty Pharma in the 3rd quarter worth $26,000. CoreCap Advisors LLC raised its position in shares of Royalty Pharma by 89.2% during the second quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 413 shares during the last quarter. Root Financial Partners LLC acquired a new position in shares of Royalty Pharma during the third quarter valued at about $62,000. Bessemer Group Inc. raised its position in shares of Royalty Pharma by 34.7% during the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 282 shares during the last quarter. Finally, IFP Advisors Inc raised its position in shares of Royalty Pharma by 263.3% during the second quarter. IFP Advisors Inc now owns 1,188 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 861 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.
Royalty Pharma Stock Performance
NASDAQ RPRX opened at $68.67 on Thursday. Royalty Pharma PLC has a twelve month low of $37.31 and a twelve month high of $70.37. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.77. The stock has a market cap of $39.39 billion, a P/E ratio of 57.23, a PEG ratio of 1.36 and a beta of 0.37. The company’s 50-day simple moving average is $61.93 and its 200 day simple moving average is $54.95.
Royalty Pharma Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a dividend of $0.2350 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend is Friday, November 13th. Royalty Pharma’s payout ratio is presently 78.33%.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on RPRX. JPMorgan Chase & Co. increased their target price on shares of Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Zacks Research upgraded Royalty Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 11th. Morgan Stanley upped their price target on Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Citigroup raised their price objective on Royalty Pharma from $70.00 to $78.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $66.00 price objective on shares of Royalty Pharma in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $65.00.
Read Our Latest Report on Royalty Pharma
Insider Buying and Selling at Royalty Pharma
In other news, EVP Marshall Urist sold 4,126 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 232,536 shares of the stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $68.87, for a total value of $16,014,754.32. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 440,788 shares of company stock valued at $29,157,162. 18.84% of the stock is currently owned by corporate insiders.
Royalty Pharma Profile
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Featured Stories
- Five stocks we like better than Royalty Pharma
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX – Free Report).
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
